Perlegen Raises $74 Million to Apply Pharmacogenomics to Drug Pipeline

Perlegen Sciences has announced the closing of a $74 million private placement of its Series D Preferred Stock with new and existing investors.

The financing was led by CSK Venture Capital, and new investors included Brookside Capital, an affiliate of Bain Capital, Mizuho Securities, Glynn Capital Management, Cape Securities and several other U.S. and European institutional investors. Previous investors also participating in the financing included Alex Zaffaroni, Maverick Capital, Lombard Odier Darier Hentsch & Cie, Zesiger Capital, Sano Ventures, BSI SA, MPM BioEquities, SB Life Sciences, Unilever Ventures, Biofrontier Partners, Private Life Biomed, CMEA Ventures and Affymetrix.

"This equity financing will enable us to continue in-licensing and developing a valuable pipeline of late-stage drugs, exploiting Perlegen's ability to target the right drugs to the right patients," said Robert Middlebrook, chief corporate development officer of Perlegen. "In addition to applying pharmacogenomics to improve drug safety, efficacy and market positioning of drugs, we look forward to expanding our collaborations with industry, government and academic researchers, with whom we are identifying genetic variations responsible for a wide range of diseases."